ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Retreat — and Pile In — Across US Markets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers are on the move. ORTEX data to August 12 shows sharp divergence between stocks gaining and losing bearish interest.

Biggest Build-Up: Replimune Jumps 10 Points

REPL saw the largest SI increase among mid-cap US stocks this week. Short interest hit 43.3% of free float, up from 32.4% just seven days ago — a jump of nearly 11 points. The oncology biotech has a cost to borrow of just 0.5%, meaning shorts are piling in cheaply.

CXW (CoreCivic) is another standout. SI leapt from 2.3% to 10.3% of free float — almost a fivefold rise in a week. Bears appear to have sharply re-rated the private prison operator.

Biggest Covers: Chewy and Asana

CHWY saw short interest fall 20 points to 94.3% of free float. That's still an enormous short position, but covering momentum is clear. ASAN dropped 8.75 points to 30.8%.

MNDY (monday.com) lost 7.2 points of SI over the week. Short sellers are stepping back from several SaaS names.

VSEC: A Short Squeeze in Progress

VSEC made headlines today. ORTEX data shows SI fell 22% in a week to 9% of free float. The stock rose 12.4% as analysts raised targets above $280. A textbook short squeeze setup.

Galectin: High Score, High Risk

GALT carries the highest ORTEX short score among notable names at 90.3. SI stands at 77.3% of free float with a cost to borrow near 15% and a DTC of 24 days. That is a very crowded short trade.

This note is for informational purposes only. Not financial advice.

Stocks in this article

How this article was generated

Generated
13 Aug 2026, 20:07
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilization

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.